Stevens S Smith1, Michael C Fiore, Timothy B Baker. 1. Department of Medicine, University of Wisconsin School of Medicine and Public Health (UWSMPH), Madison, WI, USA; Center for Tobacco Research and Intervention, UWSMPH, Madison, WI, USA.
Abstract
AIMS: To assess the relations of menthol cigarette use with measures of cessation success in a large comparative effectiveness trial (CET). DESIGN: Participants were randomized to one of six medication treatment conditions in a randomized double-blind, placebo-controlled clinical trial. All participants received six individual counseling sessions. SETTING:Community-based smokers in two communities in Wisconsin, USA. PARTICIPANTS: A total of 1504 adult smokers who smoked at least 10 cigarettes per day during the past 6 months and reported being motivated to quit smoking. The analysis sample comprised 1439 participants: 814 white non-menthol smokers, 439 white menthol smokers and 186 African American (AA) menthol smokers. There were too few AA non-menthol smokers (n = 16) to be included in the analyses. INTERVENTIONS:Nicotine lozenge, nicotine patch, bupropion sustained release, nicotine patch + nicotine lozenge, bupropion + nicotine lozenge and placebo. MEASUREMENTS: Biochemically confirmed 7-day point-prevalence abstinence assessed at 4, 8 and 26 weeks post-quit. FINDINGS: In longitudinal abstinence analyses (generalized estimating equations) controlling for cessation treatment, menthol smoking was associated with reduced likelihood of smoking cessation success relative to non-menthol smoking [model-based estimates of abstinence = 31 versus 38%, respectively; odds ratio (OR) = 0.71, 95% confidence interval (CI) = 0.59, 0.86]. In addition, among menthol smokers, AA women were at especially high risk of cessation failure relative to white women (estimated abstinence = 17 versus 35%, respectively; OR = 2.63, 95% CI = 1.75, 3.96; estimated abstinence rates for AA males and white males were both 30%, OR = 1.06, 95% CI = 0.60, 1.66). CONCLUSION: In the United States, smoking menthol cigarettes appears to be associated with reduced cessation success compared with non-menthol smoking, especially in African American females.
RCT Entities:
AIMS: To assess the relations of menthol cigarette use with measures of cessation success in a large comparative effectiveness trial (CET). DESIGN:Participants were randomized to one of six medication treatment conditions in a randomized double-blind, placebo-controlled clinical trial. All participants received six individual counseling sessions. SETTING: Community-based smokers in two communities in Wisconsin, USA. PARTICIPANTS: A total of 1504 adult smokers who smoked at least 10 cigarettes per day during the past 6 months and reported being motivated to quit smoking. The analysis sample comprised 1439 participants: 814 white non-menthol smokers, 439 white menthol smokers and 186 African American (AA) menthol smokers. There were too few AA non-menthol smokers (n = 16) to be included in the analyses. INTERVENTIONS:Nicotine lozenge, nicotine patch, bupropion sustained release, nicotine patch + nicotine lozenge, bupropion + nicotine lozenge and placebo. MEASUREMENTS: Biochemically confirmed 7-day point-prevalence abstinence assessed at 4, 8 and 26 weeks post-quit. FINDINGS: In longitudinal abstinence analyses (generalized estimating equations) controlling for cessation treatment, menthol smoking was associated with reduced likelihood of smoking cessation success relative to non-menthol smoking [model-based estimates of abstinence = 31 versus 38%, respectively; odds ratio (OR) = 0.71, 95% confidence interval (CI) = 0.59, 0.86]. In addition, among menthol smokers, AA women were at especially high risk of cessation failure relative to white women (estimated abstinence = 17 versus 35%, respectively; OR = 2.63, 95% CI = 1.75, 3.96; estimated abstinence rates for AA males and white males were both 30%, OR = 1.06, 95% CI = 0.60, 1.66). CONCLUSION: In the United States, smoking menthol cigarettes appears to be associated with reduced cessation success compared with non-menthol smoking, especially in African American females.
Authors: Karen L Cropsey; Michael F Weaver; Gloria D Eldridge; Gabriela C Villalobos; Al M Best; Maxine L Stitzer Journal: Nicotine Tob Res Date: 2009-04-22 Impact factor: 4.244
Authors: Kolawole S Okuyemi; Jasjit S Ahluwalia; Maiko Ebersole-Robinson; Delwyn Catley; Matthew S Mayo; Ken Resnicow Journal: Addiction Date: 2003-10 Impact factor: 6.526
Authors: Babalola Faseru; Nicole L Nollen; Matthew S Mayo; Ron Krebill; Won S Choi; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia; Lisa Sanderson Cox Journal: Addict Behav Date: 2012-11-29 Impact factor: 3.913
Authors: Megan E Piper; Stevens S Smith; Tanya R Schlam; Michael C Fiore; Douglas E Jorenby; David Fraser; Timothy B Baker Journal: Arch Gen Psychiatry Date: 2009-11
Authors: Janet Brigham; Christina N Lessov-Schlaggar; Harold S Javitz; Mary McElroy; Ruth Krasnow; Gary E Swan Journal: Nicotine Tob Res Date: 2008-02 Impact factor: 4.244
Authors: Kari Jo Harris; Kolawole S Okuyemi; Delwyn Catley; Matthew S Mayo; Bin Ge; Jasjit S Ahluwalia Journal: Prev Med Date: 2004-04 Impact factor: 4.018
Authors: Steven S Fu; Kolawole S Okuyemi; Melissa R Partin; Jasjit S Ahluwalia; David B Nelson; Barbara A Clothier; Anne M Joseph Journal: Nicotine Tob Res Date: 2008-03 Impact factor: 4.244
Authors: Nichole T Tanner; Nina A Thomas; Ralph Ward; Alana Rojewski; Mulugeta Gebregziabher; Benjamin A Toll; Gerard A Silvestri Journal: Chest Date: 2020-06-27 Impact factor: 9.410
Authors: Paul T Harrell; Vani N Simmons; Barbara Piñeiro; John B Correa; Nicole S Menzie; Lauren R Meltzer; Marina Unrod; Thomas H Brandon Journal: Addiction Date: 2015-08-18 Impact factor: 6.526
Authors: Philip H Smith; Biruktawit Assefa; Simranpreet Kainth; Kaliris Y Salas-Ramirez; Sherry A McKee; Gary A Giovino Journal: Nicotine Tob Res Date: 2020-03-16 Impact factor: 4.244
Authors: Pebbles Fagan; Pallav Pokhrel; Thaddeus A Herzog; Ian S Pagano; Adrian A Franke; Mark S Clanton; Linda A Alexander; Dennis R Trinidad; Kari-Lyn K Sakuma; Carl A Johnson; Eric T Moolchan Journal: Nicotine Tob Res Date: 2015-05-19 Impact factor: 4.244